IDT Acquires Oligonucleotide Synthesis Company ValueGene
News Jun 13, 2016
Integrated DNA Technologies has announced the acquisition of ValueGene, Inc. (“ValueGene”), an oligonucleotide synthesis services company based in San Diego, California.
ValueGene offers custom DNA and RNA oligonucleotide synthesis products, including PAGE and HPLC purification and modification services.
Dr Joseph A Walder, IDT founder and chief executive officer, said, “We look forward to maximizing the synergies between our two companies and building on ValueGene’s long history of providing quality products and services to its customers.”
Dan Dernbach, general manager of IDT’s West Coast operations, added, “ValueGene is well known in San Diego and Los Angeles. We welcome the opportunity to serve ValueGene’s customers and provide them the benefit of our portfolio of reagents for genomics research to support their important discoveries.”
Longze Cui of ValueGene said, “We are pleased to join IDT and are confident our customers will experience a smooth transition. Our customers, and their satisfaction, are our top priorities.”
Synthetic Material That Detects Enzymatic ActivityNews
Scientists integrate protein and polymer building blocks to create stimulus-responsive systemsREAD MORE
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE